Cargando…
Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery
BACKGROUND: The intracellular delivery of enzymes for therapeutic use has a promising future for the treatment of several diseases such as genetic disorders and cancer. Virus-like particles offer an interesting platform for enzymatic delivery to targeted cells because of their great cargo capacity a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599659/ https://www.ncbi.nlm.nih.gov/pubmed/26452461 http://dx.doi.org/10.1186/s12951-015-0127-z |
_version_ | 1782394295948410880 |
---|---|
author | Sánchez-Sánchez, Lorena Tapia-Moreno, Alejandro Juarez-Moreno, Karla Patterson, Dustin P. Cadena-Nava, Ruben D. Douglas, Trevor Vazquez-Duhalt, Rafael |
author_facet | Sánchez-Sánchez, Lorena Tapia-Moreno, Alejandro Juarez-Moreno, Karla Patterson, Dustin P. Cadena-Nava, Ruben D. Douglas, Trevor Vazquez-Duhalt, Rafael |
author_sort | Sánchez-Sánchez, Lorena |
collection | PubMed |
description | BACKGROUND: The intracellular delivery of enzymes for therapeutic use has a promising future for the treatment of several diseases such as genetic disorders and cancer. Virus-like particles offer an interesting platform for enzymatic delivery to targeted cells because of their great cargo capacity and the enhancement of the biocatalyst stability towards several factors important in the practical application of these nanoparticles. RESULTS: We have designed a nano-bioreactor based on the encapsulation of a cytochrome P450 (CYP) inside the capsid derived from the bacteriophage P22. An enhanced peroxigenase, CYPBM3, was selected as a model enzyme because of its potential in enzyme prodrug therapy. A total of 109 enzymes per capsid were encapsulated with a 70 % retention of activity for cytochromes with the correct incorporation of the heme cofactor. Upon encapsulation, the stability of the enzyme towards protease degradation and acidic pH was increased. Cytochrome P450 activity was delivered into Human cervix carcinoma cells via transfecting P22-CYP nanoparticles with lipofectamine. CONCLUSION: This work provides a clear demonstration of the potential of biocatalytic virus-like particles as medical relevant enzymatic delivery vehicles for clinical applications. |
format | Online Article Text |
id | pubmed-4599659 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45996592015-10-10 Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery Sánchez-Sánchez, Lorena Tapia-Moreno, Alejandro Juarez-Moreno, Karla Patterson, Dustin P. Cadena-Nava, Ruben D. Douglas, Trevor Vazquez-Duhalt, Rafael J Nanobiotechnology Research BACKGROUND: The intracellular delivery of enzymes for therapeutic use has a promising future for the treatment of several diseases such as genetic disorders and cancer. Virus-like particles offer an interesting platform for enzymatic delivery to targeted cells because of their great cargo capacity and the enhancement of the biocatalyst stability towards several factors important in the practical application of these nanoparticles. RESULTS: We have designed a nano-bioreactor based on the encapsulation of a cytochrome P450 (CYP) inside the capsid derived from the bacteriophage P22. An enhanced peroxigenase, CYPBM3, was selected as a model enzyme because of its potential in enzyme prodrug therapy. A total of 109 enzymes per capsid were encapsulated with a 70 % retention of activity for cytochromes with the correct incorporation of the heme cofactor. Upon encapsulation, the stability of the enzyme towards protease degradation and acidic pH was increased. Cytochrome P450 activity was delivered into Human cervix carcinoma cells via transfecting P22-CYP nanoparticles with lipofectamine. CONCLUSION: This work provides a clear demonstration of the potential of biocatalytic virus-like particles as medical relevant enzymatic delivery vehicles for clinical applications. BioMed Central 2015-10-09 /pmc/articles/PMC4599659/ /pubmed/26452461 http://dx.doi.org/10.1186/s12951-015-0127-z Text en © Sánchez-Sánchez et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sánchez-Sánchez, Lorena Tapia-Moreno, Alejandro Juarez-Moreno, Karla Patterson, Dustin P. Cadena-Nava, Ruben D. Douglas, Trevor Vazquez-Duhalt, Rafael Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery |
title | Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery |
title_full | Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery |
title_fullStr | Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery |
title_full_unstemmed | Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery |
title_short | Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery |
title_sort | design of a vlp-nanovehicle for cyp450 enzymatic activity delivery |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599659/ https://www.ncbi.nlm.nih.gov/pubmed/26452461 http://dx.doi.org/10.1186/s12951-015-0127-z |
work_keys_str_mv | AT sanchezsanchezlorena designofavlpnanovehicleforcyp450enzymaticactivitydelivery AT tapiamorenoalejandro designofavlpnanovehicleforcyp450enzymaticactivitydelivery AT juarezmorenokarla designofavlpnanovehicleforcyp450enzymaticactivitydelivery AT pattersondustinp designofavlpnanovehicleforcyp450enzymaticactivitydelivery AT cadenanavarubend designofavlpnanovehicleforcyp450enzymaticactivitydelivery AT douglastrevor designofavlpnanovehicleforcyp450enzymaticactivitydelivery AT vazquezduhaltrafael designofavlpnanovehicleforcyp450enzymaticactivitydelivery |